unknown
Stage
2021
Founded
2
Investors
About
Brenig Therapeutics develops highly selective small-molecule therapies targeting neurodegenerative diseases, with a focus on Parkinson's disease through brain-penetrant inhibitors of LRRK2 and NLRP3 inflammasome pathways.
Explore Brenig Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.